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Alemtuzumab is active in chronic lymphocytic leukaemia
(CLL) patients refractory to alkylators and fludarabine. The
aim of this study was to determine the efficacy and safety of
subcutaneous alemtuzumab at low dose (10mg three times per
week, for 18 weeks) to 49 patients with pre-treated CLL. The
overall response rate was 53%, including 27% of complete
responses; it was 42% in patients over 70 years, and 54% in the
fludarabine-resistant patients. Forty-five percent of the patients
with an unfavourable karyotype responded, including 60% of
those with the 17p- aberration. After a median follow-up of 25
months, the median overall time to disease progression was 8
months (responders 12 months, non-responders 4 months).
The median overall time to alternative treatment was 9 months
(responders 17 months, non-responders 6 months) and median
overall survival was 30 months. The treatment was well
tolerated: grade IV neutropenia was observed in 17%, and
cytomegalovirus (CMV) reactivation in 24% of the patients, with
no CMV disease. We observed a total of 30 infections (50%
during treatment and 50% during the 12-month follow-up), only
one-third of which was severe. This study confirms that low-
dose subcutaneous alemtuzumab is effective in poor prognosis
CLL, and has a particularly favourable toxicity profile.
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Introduction
Chronic lymphocytic leukaemia (CLL) patients who are refrac-
tory to front-line therapy (primarily or after an initial response)
have a poor prognosis. This is particularly true of those who are
resistant to fludarabine-containing regimens, whose life expec-
tancy is no more than 1 year regardless of therapeutic regimen.1
When treating patients with refractory CLL, great care has to
be paid to the variables that are useful in predicting therapeutic
response. Deletion 17p is very important because it has been
associated with little or no response to alkylators and
fludarabine, and with a blunted response to more complex
and efficacious fludarabine-containing regimens such as the
combination of fludarabine, cyclophosphamide and rituximab.
It is also known that new genomic aberrations (notably 17p-)
can be acquired during the course of the disease, which means
their incidence is greater in advanced CLL.2,3
Alemtuzumab is a humanised chimeric monoclonal antibody
(MoAb) that targets the CD52 antigen.4 It been found to be
effective in CLL when used alone as both front-line and salvage
therapy,5 and also seems to be effective in patients whose
leukaemic cells carry the 17p deletion.6,7 However, although
the first published studies of alemtuzumab in the treatment of
CLL go back more than 10 years,8 some areas of uncertainty still
remain. These mainly concern the fear of adverse events related
to the profound lymphopenia and associated infections induced
by the drug when the classic and consolidated intravenous
schedule of 30mg three times a week for 12 weeks is used
because, although highly effective, it may lead to infusion-
related side effects and potentially life-threatening infections.1
This is crucial when dealing with very old CLL patients (still the
majority of those who undergo treatment) and those already
severely immunocompromised by advanced disease and earlier
therapies. It has been shown that the subcutaneous administra-
tion of alemtuzumab for a longer period is highly effective as
first-line treatment, giving rise to fewer and less severe systemic
symptoms and thus leading to greater patient compliance.6,9
Favourable results have also been obtained using much lower
cumulative and per dose amounts of the drug, particularly in the
setting of maintenance/consolidation therapy.10
The aim of this article is to update our earlier findings in a
smaller cohort of patients9 concerning the safety and efficacy of
subcutaneous low-dose alemtuzumab treatment in patients with
refractory CLL. In describing the results of this less aggressive
approach to advanced CLL with alemtuzumab monotherapy,
this paper will concentrate particularly on patients with adverse
prognostic features such as the 17p deletion, an advanced
clinical stage, advanced age and fludarabine resistance.
Materials and methods
The primary objective of this prospective, multicentre, single-
arm phase II study, which involved four Italian Haematology
Units, was to verify the efficacy of low-dose alemtuzumab,
which was evaluated on the basis of the response rate, assessed
on the basis of the 1996 National Cancer Institute (NCI)
Working Group criteria,11 time to disease progression (TTP)
and time to alternative treatment (TTT) in the intention-to-treat
population.
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The secondary objectives were to assess overall survival (OS)
in the intention-to-treat population and verify the safety of the
drug, which was carried out by carefully documenting any grade
III–IV serious adverse events: that is any local and systemic first
dose reactions, or infectious complications occurring during
alemtuzumab therapy or in the 6 months after its discontinua-
tion. The study was approved by the local Ethics Committee,
and all of the patients gave their written informed consent before
enrolment, which took place between September 2003 and June
2007; the follow-up period finished in April 2008.
Patients
Adults aged more than 18 years were considered eligible for
study entry if they had a diagnosis of CLL (as defined by the 1996
NCI criteria),11 a WHO performance status of p2 and a life
expectancy of at least 3 months, were symptomatic and required
treatment, and if they had failed to respond to earlier treatment
with an alkylating agent or fludarabine. Alkylator or fludarabine
failure was defined as a failure to achieve partial or complete
remission (PR or CR) on at least one alkylator- or fludarabine-
containing regimen; disease progression while receiving alky-
lator or fludarabine treatment; or (in the case of responders)
diseases progression within 6 months of the last dose. The
additional inclusion criteria were bilirubin, aspartate amino-
transferase, alanine aminotransferase and gamma-glutamyl
transpeptidase levels less than three times the upper normal
limit, and serum creatinine levels less than twice the upper
normal range, unless the values were attributable to the disease.
The exclusion criteria were pregnancy or lactation, human
immunodeficiency virus-positive disease, active infection, or
grade IV heart failure according to the New York Heart
Association functional classification.12
Treatment schedule
Alemtuzumab 3mg was subcutaneously administered on day 1;
if this dose was well tolerated, it was increased to the target dose
of 10mg on day 3, which was subsequently given three times
weekly for a maximum of 18 weeks and a maximum cumulative
dose of 544mg. The treatment was discontinued permanently in
the case of progressive disease (PD), life-threatening infections,
grade IV haematological and/or non-haematological complica-
tions or the withdrawal of patient consent; it was temporarily
interrupted if peripheral blood neutrophil counts fell to
o1.0 109/l despite supportive granulocyte colony-stimulating
factor (G-CSF) therapy or platelet counts too 20 109/l, or in the
case of grade 4II complications.
First dose reaction prophylaxis included acetaminophen
(1 g p.o.) and antihistamines (chlorpheniramine 10mg e.v.)
given 30min before the injections; to minimise local reactions,
hydrocortisone 5mg was directly added to the alemtuzumab
solution inside the syringe. This medication was restricted to the
first 1–2 weeks depending on patient symptoms, and then
gradually withdrawn. Anti-infective prophylaxis with oral
cotrimoxazole (one tablet b.i.d. three times a week) and
acyclovir (400mg t.i.d.) was given during treatment and for at
least 2 months afterwards. The patients were monitored weekly
for cytomegalovirus (CMV) reactivation by means of early pp65
antigenemia tests until January 2006, when the tests were
replaced by CMV DNA quantification.
On enrolment, the patients underwent a physical examina-
tion, computed tomography of the thorax and abdomen, and
extensive laboratory analyses of blood parameters. Bone
marrow aspiration and a trephine biopsy were performed, and
blood or bone marrow B-CLL cells (CD19/CD5/CD23, CD38,
sIg, ZAP70) were immunophenotyped by means of flow
cytometry or immunoistochemistry. During treatment, they
underwent weekly physical examinations, blood counts with
differential, and serum electrolyte, liver and renal tests and, at
the end of treatment, a physical examination, including tumour
assessment, chest and abdominal computed tomography (if
initially abnormal), bone marrow aspiration and a trephine
biopsy. Two-colour flow cytometry was used to verify morpho-
logical CR in bone marrow.
During the follow-up, the patients underwent physical
examinations and blood counts every month between months
2 and 6, and every 3 months thereafter. Their bone marrow was
examined every 6 months after the completion of immuno-
therapy until signs of a relapse were observed.
Demographic and baseline clinical characteristics
Forty-nine patients (33 males and 16 females) were enrolled and
received alemtuzumab subcutaneously according to our proto-
col, all of who were evaluable for response (on an intention-to-
treat basis) and toxicity. Table 1 shows their baseline
characteristics. Their median age was 68 years (range 40–83):
19 patients (39%) were older than 70 years. Forty-six patients
(94%) were in Binet’s stage B or C.
Table 1 Patient demographics (n 49)
Males, n (%) 33 (67)
Females, n (%) 16 (33)
Median age, years (range) 68 (40–83)
o70 years, n (%) 30 (61)
X70 years, n (%) 19 (39)
Time since diagnosis of CLL, years (range) 62.5 (7–215)
Binet stage at study enrolment, n (%)
A 3 (6)
B 26 (53)
C 20 (41)
Unfavourable cytogenetics 31 (63)
17p- 10 (20)
Normal karyotype and isolated 13q-, n (%) 18 (37)
ZAP70+, n (%) 30 (68)
CD38+, n (%) 22 (54)
Median number of prior different regimens (range) 2 (1–5)
Type of prior therapies, n (%)
Alkylating agents 49 (100)
Fludarabine-containing regimens 26 (53)
Rituximab-containing regimens 14 (29)
Earlier infections, n (%) 29 (59)
Chronic HBV infection 3 (6)
Occult HBV infection 5 (10)
HCV 4 (8.1)
VZV 6 (12)
CMV 1 (2)
Cutaneous TBC 1 (2)
Pseudomonas aeruginosa pneumonia 1 (2)
Pseudomonas aeruginosa otitis 1 (2)
Pneumonia of unknown origin 7 (14)
Earlier haemolytic anaemia (AIHA), n (%) 7 (14)
Earlier idiopatic thrombocytopenic purpura (ITP), n (%) 1 (2)
AIHA, autoimmune haemolytic anaemia; CLL, chronic lymphocytic
leukaemia; CMV, cytomegalovirus; HBV, hepatitis B virus; HCV,
hepatitis C virus; TBC, tuberculosis; VZV, varicella zoster virus.
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Thirty-one patients (63%) showed an unfavourable cyto-
genetic profile, including 17p deletion (10 patients, 23%), 11q
deletion, trisomy 12, 6q deletion and complex abnormalities; 18
patients (37%) had a normal karyotype or isolated 13q deletion.
Fifty-four percent showed high CD38 expression, and 68% were
ZAP-70 positive.
The patients had received a median of two earlier lines of
therapy (range 1–5). All of them were refractory to alkylating
agents: 26 (53%) were also resistant to fludarabine-containing
regimens, and one-third to rituximab-containing regimens.
Twenty-nine patients (59%) had experienced at least one
infectious episode in the 6 months preceding alemtuzumab
therapy. Three patients presented chronic hepatitis B surface
antigen (HBsAg)þHBV (hepatitis B virus) infection, and a
further five had occult HBV infection. Seven patients (14%)
were diagnosed as having autoimmune haemolytic anaemia
(AIHA) during the 6 months preceding alemtuzumab therapy,
and one suffered an episode of idiopathic thrombocytopenic
purpura (ITP).
All of the patients received alemtuzumab for at least 4 weeks
(median 16 weeks; range 4–18), for a median cumulative dose
of 480mg (range 120–544). Twenty-seven patients completed
the planned treatment, and 22 discontinued the treatment
prematurely because of CR (11/49, 37%), documented PD
(5/49, 10.2%), the development of autoimmune complications
(ITP and AIHA, one patient each), grade IV infections (two
patients) or a second tumour (two patients). The treatment was
temporarily interrupted in 12 patients because of transient CMV
reactivation.
Statistical analysis
The overall response (OR¼CRþ PR) and CR rates were
estimated with their 95% confidence intervals (CIs). Overall
survival and the TTP were calculated from the start of
alemtuzumab treatment to the date of death or relapse; the
TTT was calculated from the start of alemtuzumab treatment to
the date of the change in treatment. Kaplan–Meier survival
curves (OS, TTP and TTT) were drawn up for the responders
(CRþ PR), non-responders (stable disease (SD)þ PD) and risk
factor groups (cytogenetics, age, stage, CD38/ZAP70 expres-
sion, and fludarabine and rituximab resistance), and median
survival was estimated with its approximate 95% CI. The
differences between the populations in the probability of death,
relapse or new treatment at any time point were tested using the
log-rank test. P values of less than 0.05 were considered
significant. The data were processed and statistically analysed
using version 9.1 SAS software (SAS Institute, Cary, NC, USA).
Results
Response
The OR rate according to the 1996 NCI-WG criteria was 53%
(95% CI 38–67%), and included 27% of CRs (95% CI 15–41%)
(Table 2); 10% of the patients experienced PD during the
treatment, and approximately one-third had SD at the end of
therapy. The OR rate was 42% in the patients older than 70
years.
Forty-five percent of the patients with an unfavourable
karyotype responded to alemtuzumab, compared with 69% of
those with a normal karyotype or isolated 13q deletion. The OR
rate was 60% (including 20% of CRs) in the patients with the
17p- aberration. Favourable responses were documented in
46% of the patients with CD38-positive leukaemic cells and
47% of those with ZAP70-positive cells.
When low-dose alemtuzumab was given as second-line
therapy (to 18 patients treated earlier with chlorambucil alone),
the OR rate was 50% and the CR rate as high as 33%. The
fludarabine-resistant patients showed the same OR rate as the
overall population (54%), with a slightly lower percentage of
CRs (23%); the patients who were resistant to both rituximab
Table 2 Responses by clinical and biological characteristics
Characteristic OR CR PR SD PD
Global response, n (%) 26 (53.1) 13 (26.5) 13 (26.5) 18 (36.7) 5 (10.2)
Peripheral blood, n (%) 38 (77.6) 31 (63.3) 7 (14.3) 10 (20.4) 1 (2.0)
Bone marrow, n (%) 26 (63.4) 23 (56.1) 3 (7.3) 15 (36.6) F
Lymph nodes, n (%) 26 (53.1) 16 (32.7) 10 (20.4) 18 (36.7) 5 (10.2)
Spleen, n (%) 14 (51.9) 12 (44.4) 2 (7.4) 11 (40.7) 2 (7.4)
Gender, n (%)
Male 15 (45.5) 7 (21.2) 8 (24.2) 13 (39.4) 5 (15.2)
Female 11 (68.8) 6 (37.5) 5 (31.3) 5 (31.3) 0
Unfavourable cytogenetics, n (%) 14 (43.7) 5 (15.6) 9 (28.1) 14 (43.7) 3 (9.3)
17p-, n (%) 6 (60.0) 2 (20.0) 4 (40.0) 4 (40.0) 0
Age, n (%)
o70 years 18 (60.0) 8 (26.7) 10 (33.3) 10 (33.3) 2 (6.7)
X70 years 8 (42.1) 5 (26.3) 3 (15.8) 8 (42.1) 3 (15.8)
Binet stage, n (%)
A 3 (100) 3 (100) 0 0 0
B 13 (50) 6 (23.1) 7 (26.9) 10 (38.5) 3 (11.5)
C 10 (50) 4 (20) 6 (30) 8 (40) 2 (10)
ZAP 70+, n (%) 14 (46.7) 6 (20.0) 8 (26.7) 13 (43.3) 3 (10.0)
CD38+, n (%) 10 (45.5) 5 (22.7) 5 (22.7) 9 (40.9) 3 (13.6)
Failed on fludarabine, n (%) 14 (53.8) 6 (23.1) 8 (30.8) 9 (34.6) 3 (11.5)
Failed on rituximab, n (%) 6 (42.9) 3 (21.4) 3 (21.4) 6 (42.9) 2 (14.3)
CR, complete remission; PD, progressive disease; PR, partial remission; SD, stable disease.
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and fludarabine showed an OR rate of 43%, including 21% of
CRs. The CR rate in the 20 stage C patients was lower (20%),
although the OR rate (50%) was comparable with that in the
overall population.
None of the differences in the OR or CR rates between the
considered patient subgroups based on gender, age, clinical
stage, karyotype, CD38 or ZAP70 expression, or fludarabine or
rituximab resistance was statistically significant. VHIg muta-
tional status was assessed in fewer than half of the patients, and
so no conclusion can be drawn concerning its impact on the
response to alemtuzumab therapy.
In terms of sites of leukaemic involvement, a response was
obtained in peripheral blood in 78% of the cases, in bone
marrow in 63% and in lymph nodes and spleen in 50%. The
median time to a 1-log depletion of peripheral blood lympho-
cytes was 4 weeks (range 1–16). In relation to the kinetics of
response in blood and lymph nodes, the median time to the
maximum tumour reduction was 5.5 weeks for blood, 6 weeks
for lymph nodes, 9 weeks for spleen and 15 weeks for bone
marrow.
Overall survival
After a median follow-up of 25 months (range 2–56), 27 patients
had died (55%), including 11/26 responders (42%) and 16/23
non-responders (70%) (Figure 1). The 12-month probability of
survival was 0.96±0.04 s.e. in responders and 0.65±0.10 s.e.
in non-responders, and the 24-month probability was, respec-
tively, 0.77±0.09 s.e. and 0.52±0.11. Median OS was 30
months (95% CI 25–40 months) with a significant difference
(P¼ 0.047) between responders and non-responders (Figure 1).
Five CR patients died: two in CR and three after PD. The
presence of an unfavourable cytogenetical profile did not have
an impact on survival, nor did an age of more than 70 years, the
presence of p53 deletion or the expression of CD38 or ZAP70.
Time to disease progression
Thirty-eight patients (78%) progressed during the observation
period, including 22/23 non-responders (96%) and 16/26
responders (62%) (Table 3). The median overall TTP was
8 months (95% CI 5–11months), with a significant difference
(P¼ 0.0004) between the responders (12 months, 95% CI 10–15
months) and non-responders (4 months, 95% CI 4–6 months)
(Figure 1).
Time to alternative treatment
Thirty-three patients (67%) received alternative treatment,
including 42% of the responders. The median overall TTT was
9 months (95% CI 6–12 months), with a significant difference
(Po0.0001) between responders (17 months, 95% CI 12–26
months) and non-responders (6 months, 95% CI 4–6 months)
(Figure 1).
Safety and tolerability
The alemtuzumab regimen was generally well tolerated, and
most of the observed adverse events were minor and transient.
(Table 4) Approximately two-thirds of the patients experienced
peripheral blood cytopenia, but this was WHO grades III–IV in
fewer than 5% of the anaemic patients, one-sixth of the
thrombocytopenic patients and roughly one-third of the
neutropenic patients. Alemtuzumab treatment had to be
interrupted for a median of 2 weeks (range 1–3 weeks) in nine
of the patients with an absolute neutrophil count of less than
1 109/l. First dose local reactions were generally mild–
moderate, and were limited to injection-site erythema and
oedema, which were experienced by 43 patients (88%). Only
10 patients (20.4%) developed a local grade II reaction
Figure 1 (a) Kaplan–Meier OS. Median OS was 30 months (95% CI
25–40 months) with a significant difference (P¼ 0.047) between
responders and non-responders. (b) Kaplan–Meier estimates of
progression-free survival (PFS) based on NCI 1999 criteria. Median
overall time to disease progression (TTP) was 8 months (95% CI
5–11months), with a significant difference (P¼ 0.0004) between
responders (median 12 months, 95% CI 10–15 months) and non-
responders (median 4 months, 95% CI 4–6 months). (c) Kaplan–Meier
TTT. Median overall TTT was 9 months (95% CI 6–12 months), with a
significant difference (Po0.0001) between responders (median
17 months, 95% CI 12–26 months) and non-responders (median
6 months, 95% CI 4–6 months). OS, overall survival; CRþPR,
responders; SDþ PD, non-responders; TTP, time to progression; TTT,
time to alternative treatment.
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according to version 2.0 of the National Cancer Institute
Common Toxicity Criteria. Almost one-third of the patients
experienced low-grade fever at the beginning of treatment,
which persisted beyond the first week in only two cases. None
of the patients developed any gastrointestinal, hepatic or renal
toxicity related to alemtuzumab, although one developed severe
sensitive motor peripheral polyneuropathy 6 months after
completing the treatment, which was successfully treated with
high-dose intravenous immunoglobulins.
Infectious complications were detected in 30 patients: 15
occurred during alemtuzumab treatment and 15 during the
12-month follow-up. Most of the infections recorded during the
4 months of alemtuzumab therapy were grade I/II, with only two
episodes of grade IV pulmonary complications arising in
patients with PD. Eight of the 15 infections documented during
follow-up were severe (four cases of septicemia, three of
pneumonia and one of encephalitis); six occurred in patients
with PD and two in patients in CR.
Two cases of pneumonia (one because of
Pneumocystis carinii and one to Haemophilus influenzae) were
recorded after the 12-month follow-up period (Table 4).
CMV reactivation was detected in one-quarter of the patients
during the course of the treatment. In accordance with our pre-
emptive strategy, prompt oral ganciclovir therapy was always
started in the presence of increasing titres of pp65 antigenemia/
CMV DNA, and none of the patients developed clinically
relevant CMV illness.
The combination of alemtuzumab with reverse trancriptase
inhibitors was well tolerated and effective in inhibiting HBV
proliferation. Lamivudine was started together with alemtuzu-
mab in the eight patients with earlier HBV infection. Two of the
five patients with occult HBV infection developed HBV DNA
reactivation while on alemuzumab, but this was easily
controlled by the addition of adefovir dipivoxil to lamivudine.
Alemtuzumab was safely administered to the patients with a
earlier history of autoimmune cytopenia. Four episodes of AIHA
were recorded (one during alemtuzumab therapy and three
during the follow-up period), two of which were de novo
episodes and two relapses. Three patients (including one with a
history of earlier ITP) developed an episode of ITP (one during
alemtuzumab therapy). One patient developed Evans’ syndrome
during follow-up. Evolution to diffuse large B-cell lymphoma
was documented in two of the six PR patients who died during
the follow-up.
Discussion
The treatment of relapsing/refractory CLL is still a challenge,
particularly in patients who are refractory to fludarabine-
containing regimens. The activity of alemtuzumab as a single
agent has been established in both earlier untreated and
relapsing CLL patients, including those with mutations or
deletions of the p53 gene,1,7,13 but there are still a number
Table 3 Relapse and death by response
Characteristic Total OR CR PR SD PD
Relapse or progression, n (%) 38/49 (78%) 16/26 (62.1) 8/13 (61.5) 8/13 (61.5) 17/18 (94.4) 5/5 (100)
Death, n (%) 27/49 (55%) 11/26 (42.3) 5/13 (38.5) 6/13 (46.2) 11/18 (61.1) 5/5 (100)
CR, complete remission; PD, progressive disease; PR, partial remission; SD, stable disease.
Table 4 Treatment complications
Haematological toxicity n (%)
Anaemia 30 (61.2)
Grade I 17 (56.7)
Grade II 12 (40.0)
Grade III 1 (3.3)
Grade IV 0
Neutropenia 36 (73)
Grade I 10 (28)
Grade II 13 (36)
Grade III 7 (19)
Grade IV 6 (17)
Thrombocytopenia 20 (40.8)
Grade I 15 (75.0)
Grade II 2 (10.0)
Grade III 1 (5.0)
Grade IV 2 (10.0)
Non-haematological toxicity
Injection-site reactions 43 (87.8)
Grade I 33 (76.7)
Grade II 10 (23.3)
Grade III 0
Fever (grade I/II) 14 (28.6)
Polyneuropathy 1 (2.0)
Infections
Viral reactivations during induction phase 14 (28.4)
CMV 12 (24.4)
HBV 2 (4.0)
Total infections 32 (65)
Infections during induction phase 15 (30.5)
Grade I/II 13 (26)
VZV 3 (6.1)
Fever of unknown origin 6 (12.2)
P. aeruginosa otitis 1 (2)
Localised fungal infections 3 (6)
Grade III/IV 2 (4)
Pneumonia of unknown origin 1 (2)
Aspergillus fumigatus pnemumonia 1 (2)
Infections during 12-month follow-up 15 (30.5)
Grade I/II 7 (14)
Fever of unknown origin 7 (14)
Grade III/IV 8 (16)
Pneumonia of unknown origin 3 (6)
Listeria monocytogenes encephalitis 1 (2.0)
Sepsis of unknown origin 3 (6)
P. aeruginosa sepsis
Grade III/IV infections (beyond month 12)
P. carinii pneumonia 1 (2)
H. influenzae pneumonia 2 (4)
Autoimmune complications
AIHA 4 (50)
ITP 3 (37)
Evans’ syndrome 1 (13)
AIHA, autoimmune haemolytic anaemia; HBV, hepatitis B virus; ITP,
idiopathic thrombocytopenic purpura.
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of important open questions regarding the optimal use of
alemtuzumab and MoAbs in general.
The few initial dose-finding and pharmacokinetic trials of
MoAbs were often small, and the current debate concerning the
safety and efficacy of MoAb doses in CLL has highlighted the
need to reassess the dose–response relationships of many
MoAbs.14,15 Alemtuzumab has been extensively used in the
treatment of CLL, but the classic dosing schedule was developed
empirically in the absence of sound pharmacokinetics data. The
pharmacokinetics of alemtuzumab is quite complex and non-
linear, time- and concentration-dependent and varies widely
among patients probably as a result of differences in tumour
burden. Its rate of elimination correlates directly with white
blood cell counts, becoming slower as white blood cell counts
decline as a result of the treatment. Using an improved
pharmacokinetics model to achieve adequate but not excessive
drug exposure should optimise alemtuzumab therapy (and
probably that of other MoAbs).16,17
On the basis of the classic schedule, patients undergoing
intravenous alemtuzumab therapy receive a theoretical total of
1080mg, divided into individual doses of 30mg each.
The subcutaneous route of alemtuzumab administration
(which was pioneered by researchers at the Karolinska Institute
in Sweden) rapidly became almost universally accepted because
of the dramatic reduction in the number and severity of first dose
side effects, preserved clinical efficacy and the possibility of
offering domiciliary self-administration. In 38 earlier untreated
patients, the OR rate was 87% (CR 19%, PR 68%), and the time
to treatment failure in the responders was 35þ months. In
particular, there were high response rates among patients aged
465 years and even those aged 470 years (OR 90%). It is
interesting to note that the best bone marrow response was
achieved only after 18 weeks of treatment, but was documented
in more than 50% of patients.6 The theoretical total amount of
drug delivered on the basis of this protocol is 1620mg, and the
median cumulative dose of alemtuzumab actually administered
was 1213mg.6
The efficacy of the subcutaneous route of administration was
confirmed in fludarabine-refractory CLL patients by a German
CLL Study Group trial designed to assess the relationship
between genetic abnormalities and the response to alemtuzu-
mab. The median alemtuzumab dose was 722mg (range
3–2203mg), and the OR rate was 36%, median progression-
free survival was 9.7 months, and median OS was 13.1 months.
Alemtuzumab was effective in terms of OR and OS across all
biological risk groups, including those with unmutated IgVH
genes or 17p- and/or 11q-.18
Montillo et al.10 showed that low-dose alemtuzumab can be
safely used as consolidation therapy in CLL candidates for
haematopoietic stem cell autografting, leading to in vivo purging
and an improved quality of response to earlier therapy. The
patients enrolled in this trial received alemtuzumab 10mg s.c.
three times a week for 6 weeks (cumulative dose 180mg). On
the other hand, alemtuzumab consolidation (30mg three times
per week) was associated with a risk of severe infectious events
when it was given shortly after induction therapy,19 and when it
was used after induction therapy including rituximab.20,21
In our study, we prospectively explored the possibility of
obtaining equally positive results while avoiding untoward
effects using a much lower dose of alemtuzumab (a theoretical
cumulative dose 540mg, and a median actual cumulative dose
of 480mg) than the classic dose: that is half cumulative and
one-third individual dose.
An initial pilot study of 16 CLL patients showed that this
approach was well tolerated and effective,9 and the final results
of our trial indicated that fairly prolonged but non-aggressive
alemtuzumab monotherapy leads to a high OR rate (53%,
including 26% of CRs) in patients with advanced and pretreated
CLL who had become refractory to their last anti-leukaemic
treatment. In line with earlier reported observations,6 the blood,
lymph node and spleen responses were quite rapid, but bone
marrow response was slower than that observed using the
classic i.v. schedule, thus confirming the need for a longer time
of alemtuzumab administration when given subcutaneously.
It is worth pointing out that these results were obtained
despite the decreased bioavailability of s.c. administered
alemtuzumab,22 and the fact that we used a substantially lower
dose than that used in earlier reported studies involving similar
subsets of patients.1,6,18,23 The responses were equally good
regardless of the presence of clinical or biological factors known
to have an impact on CLL prognosis, such as and advanced age
or clinical stage, an unfavourable karyotype (particularly 17p
deletion), CD38 or ZAP70-positive leukaemic cells and
refractoriness to alkylating agents and purine analogues.
Importantly, in comparison with the patients who did not show
a substantial response (that is, those with SD) or who progressed
while receiving alemtuzumab, the responders experienced a
significantly prolonged TTP (12 vs 4 months) and TTT (17 vs
6 months). Finally, life expectancy also seemed to be affected by
a positive result, as the survival of the responders was longer,
although the difference was only of borderline statistical
significance.
These favourable efficacy results were coupled with a positive
toxicity profile. Only a few and short-lived immediate reactions
were recorded: albeit frequently observed, injection-site reac-
tions were generally very mild and transient, whereas systemic
reactions were notably absent. This low level of local toxicity
may have been because of our policy of combining alemtuzu-
mab with low-dose hydrocortisone in the same syringe, even
though equally positive tolerability has been described with and
without systemic steroid prophylaxis.6,23
Although the incidence of CMV reactivation was substantial,
it was in line with earlier reports.4,24 Furthermore, the patients
with CMV reactivation showed no clinical signs of CMV disease
and, once the CMV had been rapidly cleared be means of pre-
emptive oral ganciclovir therapy, they could all safely resume
taking alemtuzumab.
The incidence of infectious episodes was also substantial, but
once again in line with earlier published data concerning
advanced CLL patients treated with alemtuzumab or other-
wise.4,17 There were 30 infectious complications, half of which
occurred during treatment and half during the 12-month follow-
up: that is 0.6 episodes per patient for the entire observation
period. Furthermore, only one-third of the infections was severe
or life-threatening (0.2 episodes per patient).
The costs of low-dose therapy are in principle half those of the
classic i.v. schedule and less than half of those of full-dose
alemtuzumab s.c. for 18 weeks. One technical problem when
giving patients 10mg individual doses is the fact that the current
galenic size of alemtuzumab is 30mg per ampoule. Vermeulen
et al.25 have shown that it is possible to prepare multiple doses
of alemtuzumab from a single vial, store them refrigerated and
safely administer them within 28 days, with a significant impact
on cost. Nevertheless, our experience and that of other authors
using low-dose Campath (for example, for maintenance/
consolidation) indicates a need for a 10mg ampoule formulation.
Our experience raises the question of appropriately selecting
‘ideal’ patients with refractory CLL for low-dose s.c. alemtuzu-
mab treatment. Our study population was highly sensitive to
Campath, regardless of the presence of a number of negative
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clinical and biological prognostic factors: in particular, neither
old age nor advanced clinical stage seemed to be limiting
factors, and a very good response was also documented in
patients whose leukaemic cells carried the 17p- alteration.
However, the majority of our patients (44/49) had a WHO
performance status (PS) ofo2. Moreover, the response obtained
in the five patients with a PS of 2 was very poor: that is one SD
and four PDs. The results obtained in the four patients with
bulky nodes were also very poor (1 PR and 3 SDs). We therefore
fully agree with the conclusions reached by Karlsson et al. that
the success of alemtuzumab therapy greatly depends on factors
such as a good performance status, the absence of bulky lymph
nodes and continuing therapy as planned by appropriately
managing predictable adverse events.
Taken together, our data can be considered as marking a step
towards the easier and less aggressive use of alemtuzumab, and
may reduce the fear of adverse effects even in CLL patients who
are very old or have pre-treated disease and a poor prognosis.
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